Activation of coagulation with concurrent impairment of anticoagulant mechanisms correlates with a poor outcome in severe melioidosis

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 1, 2008, Pages 32-39

  Wiersinga, W J ^a   Meijers, J C M ^a   Levi, M ^a   Van 't Veer, C ^a   Day, N P ^b,c   Peacock, S J ^b,c   van der Poll, T ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b MAHIDOL UNIVERSITY   (Thailand)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Burkholderia pseudomallei; Melioidosis; Protein C; Sepsis; Tissue factor

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTIINFECTIVE AGENT; ANTITHROMBIN; D DIMER; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOMODULIN; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BACTERIUM CULTURE; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEATH; DISEASE SEVERITY; FEMALE; FIBRINOLYSIS; GRAM NEGATIVE SEPSIS; HOSPITAL ADMISSION; HUMAN; HUMAN CELL; MALE; MELIOIDOSIS; MORTALITY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; SURVIVOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CASE-CONTROL STUDIES; FEMALE; FIBRINOLYSIS; HUMANS; MALE; MELIOIDOSIS; MIDDLE AGED; PROGNOSIS; SEPSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 37549065147     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02796.x     Document Type: Article

References (40)

1. Wiersinga WJ, van der Poll T, White NJ, Day NP, Peacock SJ. Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei. Nat Rev Microbiol 2006; 4: 272-82.
2. Cheng AC, Currie BJ. Melioidosis: Epidemiology, pathophysiology, and management. Clin Microbiol Rev 2005; 18: 383-416.
3. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 2005; 365: 63-78.
4. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 2003; 31: 1250-6.
5. Levi M, ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586-92.
6. van der Poll T. Immunotherapy of sepsis. Lancet Infect Dis 2001; 1: 165-74.
7. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol 2005; 131: 417-30.
8. Levi M, van der Poll T, Buller HR. Bidirectional relation between inflammation and coagulation. Circulation 2004; 109: 2698-704.
9. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
10. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: A randomized controlled trial. JAMA 2001; 286: 1869-78.
11. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De Deyne C, Postier R, Pettila V, Artigas A, Percell SR et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. JAMA 2003; 290: 238-47.
12. Wiersinga WJ, Dessing MC, Kager PA, Cheng AC, Limmathurotsakul D, Day NP, Dondorp AM, van der Poll T, Peacock SJ. High-Throughput mRNA profiling characterizes the expression of inflammatory molecules in sepsis caused by Burkholderia pseudomallei. Infect Immun 2007; 75: 3074-9.
13. Renckens R, Roelofs JJ, Florquin S, de Vos AF, Pater JM, Lijnen HR, Carmeliet P, van 't Veer C, van der Poll T. Endogenous tissue-type plasminogen activator is protective during Escherichia coli -induced abdominal sepsis in mice. J Immunol 2006; 177: 1189-96.
14. Lupberger J, Kreuzer KA, Baskaynak G, Peters UR, le Coutre P, Schmidt CA. Quantitative analysis of beta-actin, beta-2-microglobulin and porphobilinogen deaminase mRNA and their comparison as control transcripts for RT-PCR. Mol Cell Probes 2002; 16: 25-30.
15. Sandset PM, Abildgaard U, Pettersen M. A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions. Thromb Res 1987; 47: 389-400.
16. Kario K, Matsuo T, Kodama K, Matsuo M, Yamamoto K, Kobayashi H. Imbalance between thrombin and plasmin activity in disseminated intravascular coagulation. Assessment by the thrombin-antithrombin-III complex/plasmin-alpha-2-antiplasmin complex ratio. Haemostasis 1992; 22: 179-86.
17. van der Poll T, Levi M, Dentener M, Jansen PM, Coyle SM, Braxton CC, Buurman WA, Hack CE, ten Cate JW, Lowry SF. Epinephrine exerts anticoagulant effects during human endotoxemia. J Exp Med 1997; 185: 1143-8.
18. Osterud B, Flaegstad T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: Related to an unfavourable prognosis. Thromb Haemost 1983; 49: 5-7.
19. de Jonge E, Dekkers PE, Creasey AA, Hack CE, Paulson SK, Karim A, Kesecioglu J, Levi M, van Deventer SJ, van der Poll T. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 2000; 95: 1124-9.
20. Taylor FB Jr, Chang A, Ruf W, Morrissey JH, Hinshaw L, Catlett R, Blick K, Edgington TS. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991; 33: 127-34.
21. Levi M, ten Cate H, Bauer KA, van der Poll T, Edgington TS, Buller HR, van Deventer SJ, Hack CE, ten Cate JW, Rosenberg RD. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994; 93: 114-20.
22. Nakamura S, Imamura T, Okamoto K. Tissue factor in neutrophils: Yes. J Thromb Haemost 2004; 2: 214-7.
23. Osterud B. Tissue factor in neutrophils: No. J Thromb Haemost 2004; 2: 218-20.
24. Aras O, Shet A, Bach RR, Hysjulien JL, Slungaard A, Hebbel RP, Escolar G, Jilma B, Key NS. Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia. Blood 2004; 103: 4545-53.
25. Piccin A, Murphy WG, Smith OP. Circulating microparticles: pathophysiology and clinical implications. Blood Rev 2007; 21: 157-71.
26. Breimo ES, Osterud B. Generation of tissue factor-rich microparticles in an ex vivo whole blood model. Blood Coagul Fibrinolysis 2005; 16: 399-405.
27. Soriano AO, Jy W, Chirinos JA, Valdivia MA, Velasquez HS, Jimenez JJ, Horstman LL, Kett DH, Schein RM, Ahn YS. Levels of endothelial and platelet microparticles and their interactions with leukocytes negatively correlate with organ dysfunction and predict mortality in severe sepsis. Crit Care Med 2005; 33: 2540-6.
28. Gando S, Kameue T, Morimoto Y, Matsuda N, Hayakawa M, Kemmotsu O. Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis. Crit Care Med 2002; 30: 1729-34.
29. Raaphorst J, Johan Groeneveld AB, Bossink AW, Erik Hack C. Early inhibition of activated fibrinolysis predicts microbial infection, shock and mortality in febrile medical patients. Thromb Haemost 2001; 86: 543-9.
30. Mesters RM, Florke N, Ostermann H, Kienast J. Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemost 1996; 75: 902-7.
31. Kinasewitz GT, Yan SB, Basson B, Comp P, Russell JA, Cariou A, Um SL, Utterback B, Laterre PF, Dhainaut JF. Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]. Crit Care 2004; 8: R82-90.
32. Dhainaut JF, Shorr AF, Macias WL, Kollef MJ, Levi M, Reinhart K, Nelson DR. Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure. Crit Care Med 2005; 33: 341-8.
33. Dhainaut JF, Yan SB, Joyce DE, Pettila V, Basson B, Brandt JT, Sundin DP, Levi M. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004; 2: 1924-33.
34. LaRosa SP, Opal SM, Utterback B, Yan SC, Helterbrand J, Simpson AJ, Chaowagul W, White NJ, Fisher CJ Jr. Decreased protein C, protein S, and antithrombin levels are predictive of poor outcome in Gram-negative sepsis caused by Burkholderia pseudomallei. Int J Infect Dis 2006; 10: 25-31.
35. Levi M, van der Poll T. Two-way interactions between inflammation and coagulation. Trends Cardiovasc Med 2005; 15: 254-9.
36. van der Poll T, Buller HR, ten Cate H, Wortel CH, Bauer KA, van Deventer SJ, Hack CE, Sauerwein HP, Rosenberg RD, ten Cate JW. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322: 1622-7.
37. Jansen PM, Boermeester MA, Fischer E, de Jong IW, van der Poll T, Moldawer LL, Hack CE, Lowry SF. Contribution of interleukin-1 to activation of coagulation and fibrinolysis, neutrophil degranulation, and the release of secretory- type phospholipase A2 in sepsis: Studies in nonhuman primates after interleukin-1 alpha administration and during lethal bacteremia. Blood 1995; 86: 1027-34.
38. Stouthard JM, Levi M, Hack CE, Veenhof CH, Romijn HA, Sauerwein HP, van der Poll T. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost 1996; 76: 738-42.
39. Lauw FN, Dekkers PE, te Velde AA, Speelman P, Levi M, Kurimoto M, Hack CE, van Deventer SJ, van der Poll T. Interleukin-12 induces sustained activation of multiple host inflammatory mediator systems in chimpanzees. J Infect Dis 1999; 179: 646-52.
40. Atisook K, Panyathanya R. Acute systemic melioidosis: An autopsy study of six cases. Southeast Asian J Trop Med Public Health 1988; 19: 637-42.